Cornell
Trial will test whether surgery is the best option for type 2 diabetes
NEW YORK (Feb. 10, 2011) — A new clinical trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is among the first to test surgery specifically for Type 2 diabetes. The aim of the study is to understand whether surgery can control d…
Sweeping view of prostate cancer genome yields deep insights
NEW YORK, CAMBRIDGE, Mass., AND BOSTON (Feb. 9, 2011) — For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of t…
Choices — not discrimination — determine success for women scientists, Cornell researchers say
ITHACA, N.Y. — It’s an incendiary topic in academia — the pervasive belief that women are underrepresented in science, math and engineering fields because they face sex discrimination in the interviewing, hiring, and grant and manuscript review …
Cornell researchers find a strong community protects adolescents from risky health behavior
ITHACA, N.Y. — Growing up poor increases a person’s likelihood of health problems as an adult, but a new study led by a Cornell University environmental psychologist shows that being raised in a tight-knit community can help offset this disadvanta…
Technique allows researchers to identify key maize genes for increased yield
ITHACA, N.Y. — Scientists have identified the genes related to leaf angle in corn (maize) — a key trait for planting crops closer together, which has led to an eight-fold increase in yield since the early 1900s. (Nature Genetics, Jan. 9, 2011.)…
Team creates novel vaccine that produces strong immunity against cocaine high
LA JOLLA, CA — January 4, 2011 — Researchers from The Scripps Research Institute, Weill Cornell Medical College, and Cornell University have produced a long-lasting anti-cocaine immunity in mice by giving them a unique vaccine that combines bi…
Prostate cancer’s multiple personalities revealed
NEW YORK (Nov. 3, 2010) — Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors…
New lymphoma therapy may be more effective with fewer side effects
NEW YORK (Nov. 3, 2010) — Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin’s lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a c…